Clinical Trial Detail

NCT ID NCT03276832
Title Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Mayo Clinic
Indications

melanoma

Therapies

Imiquimod + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.